spacer
home > ict > winter 2018 > clinical acceleration
PUBLICATIONS
International Clinical Trials

Clinical Acceleration

The development of therapies for central nervous system (CNS) diseases has lagged behind other areas, despite these diseases affecting over one billion individuals worldwide (1). As the population ages, the incidence of disorders like Alzheimerís disease, Parkinsonís disease, and stroke are expected to rise, further increasing their impact on society.

CNS drugs take longer on average than drugs in other therapeutic areas and are half as likely to reach the market (2). Development programmes in CNS are lengthier and more complex for several reasons; the most consequential of which include the heterogeneous nature of CNS disorders, suboptimal preclinical models, bloodbrain- barrier penetration impediments, and challenges in recruitment and retention of patients. Furthermore, overly lengthy development timelines can shorten the initial investment time span of a new compound. Changing or unestablished regulatory requirements can halt drug development if they occur too late in the process for the clinical development plan to be adapted. The pharmaceutical industry needs new strategies to increase the success rate of CNS therapy development and approval.

Over the past few years, there has been a trend for pharma companies to target orphan indications, essentially utilising rare diseases to obtain the initial clinical proof-of-concept and approval for a compound. This approach offers advantages in a competitive landscape, minimising risk and potentially availing new or repurposed drugs to eventually be studied in broader indications. With the growing number of gene therapies targeting subpopulations in diseases like muscular dystrophy, Huntington's disease, Friedreich's ataxia, etc, studies in smaller homogenous CNS populations are often appropriate.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Kemi Olugemo is a Neurologist and Senior Medical Director at PAREXEL. She received her bachelorís degree from the University of Massachusetts, US, and her MD from the University of Maryland School of Medicine, US. Kemi initially joined PAREXEL International in September 2011 as a Clinical Research Physician. She served as the Principal Investigator or Sub-Investigator for over 50 studies spanning from Phase 1-4 in several therapeutic areas, including CNS, oncology, endocrine, cardiovascular, and infectious disease. Kemi re-joined PAREXEL International as Medical Director in June 2014. Her current responsibilities include medical monitoring; consulting in clinical drug development from pre-clinical through post-marketing, support for protocol development, regulatory submissions, and manuscript development; training on therapeutic areas, specific disease states, adverse events assessment/ management; and addressing medical and scientific questions for PAREXEL. Kemi is certified by the American Board of Psychiatry and Neurology
spacer
Dr Kemi Olugemo
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Serialization Installation at Tredegar Manufacturing Center of Excellence

PCI Pharma Services (PCI) is pleased to announce the installation and validation of its latest comprehensive Serialization system, located at its manufacturing Center of Excellence in Tredegar, UK.  The investment demonstrates PCIís continued investment in and expansion of market-leading Serialization capabilities. This latest installation increases PCIís Serialization capability to support clients in advance of implementation dates for the European Falsified Medicines Directive (EU FMD), as well as supply for the US and emerging markets, including countries such as China, Turkey, Brazil, Saudi Arabia and others.  PCIís system is compliant to all EU member country requirements for Serialization and specialized labeling, including application and integration of advanced Anticounterfeiting technologies.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

 
Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement